Molecular diagnostics company Biodesix announced that it has closed $8.4 million in Series E financing. Current shareholders provided all the revenue, with $4 million arising from a convertible note and the remainder from new funds.
The company specializes in diagnostics for personalized medicine and will use the capital to improve its ProTS technology platform and to market its first product, the serum protein test VeriStat, to guide treatment for advanced non-small cell lung cancer (NSCLC) patients.
“Biodesix is a growing company with a strong pipeline,” said David Brunel, the company’s chief executive officer. “In securing this investment, we are well positioned to effectively deliver game-changing diagnostics to guide physician decisions and improve patient outcomes.”
Biodesix was founded in 2005, using mass spectrometry to develop multivariate tests for understanding and treatment of disease. For more information, visit Biodesix.
